Skip to main content

Cell and Gene Therapy

Guiding the way to precision targeting discovery

The recent success of cell and gene therapies has paved the way for the next generation of advanced therapeutics. While challenges remain, cell and gene therapy research is seeing a transformational shift in the way that novel modalities, such as CAR-T, CRISPR, and vectors, are developed and delivered.

Advances in gene and cell therapy include customized options where the delivery vehicle aims to correct the monogenic aberration using in vivo gene editing approaches or harness the immune system at the cellular level using ex vivo approaches.

Our integrated cell and gene therapy workflows support precise gene editing, accurate cell analysis, optimization of AAV and lentiviral vector development, and manufacturing to improve the specificity, efficacy, and safety of cell and gene delivery.

Our solutions range from functional genomics, payload design, and vector optimization to characterization, automation, and process development. Let’s partner so we can find out how we can assist your cell and gene therapy research, development, and manufacturing goals.

Key features:
  • Innovative solutions for cell and gene therapy research
  • Tools for CRISPR gene editing and viral vector analysis
  • Advanced technologies for stem cell characterization
  • Comprehensive gene expression analysis for therapy development
cell-and-gene-therapy-video-thumb.jpg

For research use only. Not for use in diagnostic procedures.

gene-therapy-512x288.jpg
Gene Therapy

Optimize your gene therapy workflows​

Gene editing technologies have shown to optimize functional genomics, genetic screening, target identification and nucleotide payload development to elevate gene therapy research.

Optimize your gene therapy workflows​

Gene editing technologies have shown to optimize functional genomics, genetic screening, target identification and nucleotide payload development to elevate gene therapy research.

In vivo gene editing uses a delivery vehicle such as a virus, for example an adeno-associated virus (AAV), or a non-viral nanoparticle which can target the gene of interest to the disease-associated tissue or organ.

We offer enablement and transformative solutions for your gene therapy discovery, development, and manufacturing processes:

  • Improve your CRISPR gene editing workflows​
  • Design and characterize your delivery vector and payload cassette ​
  • Monitor the safety and efficacy of the biotherapeutic​
  • Evaluate and document your Critical Quality Attributes (CQAs)

Learn more

cell-counters-512x288.jpg
Cell Therapy

Elevate your cell therapy programs​

Depending on availability, immunocompatibility, and sample source, cell-based therapies can be segmented into two categories: autologous and allogenic.

Elevate your cell therapy programs​

Depending on availability, immunocompatibility, and sample source, cell-based therapies can be segmented into two categories: autologous and allogenic.

Autologous therapies are customized to an individual’s needs, in which cells are enriched, modified, and injected back into the same individual to elicit a desired immunotherapeutic response.

In allogeneic cell-based therapies, cells or tissue (e.g., bone marrow, adipose fat) from unrelated donors are banked in large batches using Good Manufacturing Practices (GMP) to treat larger populations.​

We offer enablement and transformative cellular therapy products for your discovery, development, and scale up processes:

  • Accurately count and characterize both subject or donor-derived cells
  • Enrich, expand, and engineer your desired cells for CAR-T programs​
  • Establish well-defined immunoassay protocols to measure cell signaling and protein binding activity​
  • Evaluate and document your Critical Quality Attributes (CQAs)

Explore our cell and gene therapy solutions

Questions?
We’re here to help.

Contact us

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.